![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RB Clark, C Allal, J Friedman, M Johnson and R Barber
University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences 77225-0334, USA.
The relaxation of tracheal smooth muscle by the beta 2-adrenergic receptor (beta AR) agonist salmeterol displays several unusual properties: (i) slow onset of action (t1/2 = 5-15 min), (ii) prolonged activation (t1/2 = 8-14 hr), and (iii) the ability to recover from beta AR blockade. These properties led to the hypothesis that salmeterol binds with very high affinity to an exosite in addition to the beta AR activating site. Despite extensive characterization of salmeterol- induced bronchodilation, little is known about the molecular actions of salmeterol. We report the unique properties of salmeterol binding to the beta AR, activation of adenylyl cyclase, and desensitization of the hamster beta AR expressed in L cells. First, we found that salmeterol activation of adenylyl cyclase, although rapid and potent (low EC50 relative to epinephrine), was nevertheless remarkably inefficient relative to the full agonist epinephrine. Reduced coupling efficiency of salmeterol was demonstrated using formulations recently introduced by our group. Second, we found that pretreatment of L cells with salmeterol led to a stable activation of adenylyl cyclase that survives extensive wash procedures and sucrose step gradient purification of plasma membrane fractions. This activation of basal adenylyl cyclase did not require salmeterol binding to the classic active site during pretreatment, as it occurred in the presence of an excess of a beta AR antagonist. Third, we found that the rapid phase of salmeterol-induced desensitization was much reduced relative to epinephrine, consistent with its poor coupling efficiency and with its prolonged activation of adenylyl cyclase. These unique properties of salmeterol support the proposal that it binds reversibly to the activating or active site and as well to an extremely high affinity exosite from which it has access to the active site.
This article has been cited by other articles:
|
|
 |
|
  M. R. Edwards, M. W. Johnson, and S. L. Johnston Combination Therapy: Synergistic Suppression of Virus-Induced Chemokines in Airway Epithelial Cells Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 616 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Maris, K. F. van der Sluijs, S. Florquin, A. F. de Vos, J. M. Pater, H. M. Jansen, and T. van der Poll Salmeterol, a {beta}2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1122 - L1128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Tran, J. Friedman, E. Qunaibi, F. Baameur, R. H. Moore, and R. B. Clark Characterization of Agonist Stimulation of cAMP-Dependent Protein Kinase and G Protein-Coupled Receptor Kinase Phosphorylation of the {beta}2-Adrenergic Receptor Using Phosphoserine-Specific Antibodies Mol. Pharmacol., January 1, 2004; 65(1): 196 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Friedman, B. Babu, and R. B. Clark beta 2-Adrenergic Receptor Lacking the Cyclic AMP-Dependent Protein Kinase Consensus Sites Fully Activates Extracellular Signal-Regulated Kinase 1/2 in Human Embryonic Kidney 293 Cells: Lack of Evidence for Gs/Gi Switching. Mol. Pharmacol., November 1, 2002; 62(5): 1094 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jakubik, S. Tucek, and E. E. El-Fakahany Allosteric Modulation by Persistent Binding of Xanomeline of the Interaction of Competitive Ligands with the M1 Muscarinic Acetylcholine Receptor J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. RENNARD, W. ANDERSON, R. ZuWALLACK, J. BROUGHTON, W. BAILEY, M. FRIEDMAN, M. WISNIEWSKI, and K. RICKARD Use of a Long-acting Inhaled {beta}2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1087 - 1092. [Abstract] [Full Text]
|
|
|
|
|
|
G. P. ANDERSON Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S188 - 196. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Groeben and C. Emala Is {beta}-Adrenergic-Mediated Airway Relaxation of Salmeterol Antagonized by Its Solvent Xinafoic Acid? Chest, June 1, 1999; 115(6): 1678 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Teschemacher and H. Lemoine Kinetic Analysis of Drug-Receptor Interactions of Long-Acting beta 2 Sympathomimetics in Isolated Receptor Membranes: Evidence against Prolonged Effects of Salmeterol and Formoterol on Receptor-Coupled Adenylyl Cyclase J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1084 - 1092. [Abstract] [Full Text]
|
|
|
|
|
|
R. B. Penn, J.-L. Parent, A. N. Pronin, R. A. Panettieri Jr., and J. L. Benovic Pharmacological Inhibition of Protein Kinases in Intact Cells: Antagonism of Beta Adrenergic Receptor Ligand Binding by H-89 Reveals Limitations of Usefulness J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 428 - 437. [Abstract] [Full Text]
|
|
|
|
|
|
A. Christopoulos, T. L. Pierce, J. L. Sorman, and E. E. El-Fakahany On the Unique Binding and Activating Properties of Xanomeline at the M1 Muscarinic Acetylcholine Receptor Mol. Pharmacol., June 1, 1998; 53(6): 1120 - 1130. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Kallal, A. W. Gagnon, R. B. Penn, and J. L. Benovic Visualization of Agonist-induced Sequestration and Down-regulation of a Green Fluorescent Protein-tagged beta 2-Adrenergic Receptor J. Biol. Chem., January 2, 1998; 273(1): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. January, A. Seibold, B. Whaley, R. W. Hipkin, D. Lin, A. Schonbrunn, R. Barber, and R. B. Clark beta 2-Adrenergic Receptor Desensitization, Internalization, and Phosphorylation in Response to Full and Partial Agonists J. Biol. Chem., September 19, 1997; 272(38): 23871 - 23879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Green, A. P. Spasoff, R. A. Coleman, M. Johnson, and S. B. Liggett Sustained Activation of a G Protein-coupled Receptor via ``Anchored'' Agonist Binding. MOLECULAR LOCALIZATION OF THE SALMETEROL EXOSITE WITHIN THE beta 2-ADRENERGIC RECEPTOR J. Biol. Chem., September 27, 1996; 271(39): 24029 - 24035. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
